Vedolizumab in Ulcerative Colitis; A Budget Impact Model for a Novel Drug in a Recession Environment

Value in Health - United Kingdom
doi 10.1016/j.jval.2015.09.2185
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Combination Therapy With Vedolizumab and Tofacitinib in a Patient With Ulcerative Colitis and Spondyloarthropathy

Clinical Gastroenterology and Hepatology
HepatologyGastroenterology
2019English

Activity-Based Costing and Budget Analysis of Vedolizumab Versus Conventional Treatments in Ulcerative Colitis and Crohn’s Disease

Global and Regional Health Technology Assessment
Health Policy
2017English

Ulcerative Colitis as a Novel Cause of Increased Need for Levothyroxine

Frontiers in Endocrinology
EndocrinologyMetabolismDiabetes
2019English

Vedolizumab Exposure Levels and Clinical Outcomes in Ulcerative Colitis: Determining the Potential for Dose Optimisation

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2019English

Ulcerative Colitis in a Husband and Wife.

Gut
Gastroenterology
1994English

Histiocytic Ulcerative Colitis in a French Bulldog

Journal of Veterinary Medical Science
Veterinary
2003English

Current and Novel Treatments for Ulcerative Colitis

2012English

Leclercia adecarboxylataBacteremia in a Patient With Ulcerative Colitis

Case Reports in Gastrointestinal Medicine
2014English

Anti‑inflammatory Effects of Fagopyrum Cymosum Administered as a Potential Drug for Ulcerative Colitis

Experimental and Therapeutic Medicine
MedicineCancer ResearchImmunologyMicrobiology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy